Curis vs Molecular Partners
CRIS and MOLN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRIS and MOLN compare
Curis grew revenue faster over the last twelve months (−62.2% versus −100% for Molecular Partners).
Curis scores higher on the StockData Score (7 against 1 for Molecular Partners), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRIS | MOLN |
|---|---|---|
| Size and price | ||
| Market cap | $1.2M | – |
| Share price | $0.592 | $3.09 |
| Change, 1 year | −97.7% | −27.3% |
| Change, 5 years | −100.0% | −70.4% |
| Beta (5Y) | 1.95 | 0.90 |
| Employees | 24 | 34 |
| StockData Score | ||
| Total score | 7 (better) | 1 |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.3× | – |
| P/B | 0.3× | – |
| Fair value | $6.77 | – |
| Margin of safety | 91.3% | – |
| Growth | ||
| Revenue growth (TTM) | −62.2% (better) | −100% |
| Revenue growth, 5Y average | −2.7% | – |
| Profitability | ||
| Operating margin | −203% | – |
| Net margin | −490% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −11.5× |
| Current ratio | 0.49 | 7.27 (better) |
| Altman Z-score | −96.16 | – |
| Piotroski F-score | 3 | – |
| Dividends and buybacks | ||
| Buyback yield | −1989% | – |
| Shareholder yield | −1989% | – |
| Ownership | ||
| Held by institutions | 32.1% | 8.9% |
| Held by insiders | 20.4% | 0.00% |
| Insider net buying, 12 months | $5.5K | – |
| Short interest, % of float | 61.8% | – |
Go deeper
- CRIS stock overview
- CRIS income statement
- CRIS valuation and score
- MOLN stock overview
- MOLN income statement
- MOLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.